NO20024932D0 - Kontrastmiddel - Google Patents

Kontrastmiddel

Info

Publication number
NO20024932D0
NO20024932D0 NO20024932A NO20024932A NO20024932D0 NO 20024932 D0 NO20024932 D0 NO 20024932D0 NO 20024932 A NO20024932 A NO 20024932A NO 20024932 A NO20024932 A NO 20024932A NO 20024932 D0 NO20024932 D0 NO 20024932D0
Authority
NO
Norway
Prior art keywords
imaging agents
agents
receptors
binds
based compounds
Prior art date
Application number
NO20024932A
Other languages
English (en)
Other versions
NO331741B1 (no
Inventor
Bente Arbo
Alan Cuthbertson
Baard Indrevoll
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009042A external-priority patent/GB0009042D0/en
Priority claimed from GB0025070A external-priority patent/GB0025070D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Priority to NO20024932A priority Critical patent/NO331741B1/no
Publication of NO20024932D0 publication Critical patent/NO20024932D0/no
Publication of NO331741B1 publication Critical patent/NO331741B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen dreier seg om nye peptidbaserte forbindelser til bruk som bildediagnostiske midler eller som terapeutika hvor midlene inneholder en målstyrt vektor som bindes til reseptorer som er forbundet med integrinreseptorer.
NO20024932A 2000-04-12 2002-10-14 Peptidbaserte forbindelser som har affinitet for integrinreseptorer, farmasoytiske sammensetninger omfattende slike og bruk av disse for fremstilling av et kontrastmiddel og et medikament. NO331741B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20024932A NO331741B1 (no) 2000-04-12 2002-10-14 Peptidbaserte forbindelser som har affinitet for integrinreseptorer, farmasoytiske sammensetninger omfattende slike og bruk av disse for fremstilling av et kontrastmiddel og et medikament.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0009042A GB0009042D0 (en) 2000-04-12 2000-04-12 Contrast agents
GB0025070A GB0025070D0 (en) 2000-10-12 2000-10-12 Contrast agents
PCT/NO2001/000146 WO2001077145A2 (en) 2000-04-12 2001-04-06 Integrin binding peptide derivatives
NO20024932A NO331741B1 (no) 2000-04-12 2002-10-14 Peptidbaserte forbindelser som har affinitet for integrinreseptorer, farmasoytiske sammensetninger omfattende slike og bruk av disse for fremstilling av et kontrastmiddel og et medikament.

Publications (2)

Publication Number Publication Date
NO20024932D0 true NO20024932D0 (no) 2002-10-14
NO331741B1 NO331741B1 (no) 2012-03-19

Family

ID=26244091

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024932A NO331741B1 (no) 2000-04-12 2002-10-14 Peptidbaserte forbindelser som har affinitet for integrinreseptorer, farmasoytiske sammensetninger omfattende slike og bruk av disse for fremstilling av et kontrastmiddel og et medikament.

Country Status (16)

Country Link
US (2) US7351790B2 (no)
EP (1) EP1272507B1 (no)
JP (1) JP5043271B2 (no)
KR (2) KR100866666B1 (no)
CN (1) CN1230441C (no)
AT (1) ATE298763T1 (no)
AU (2) AU2001250683B2 (no)
CA (1) CA2405469C (no)
DE (1) DE60111733T2 (no)
DK (1) DK1272507T3 (no)
ES (1) ES2244607T3 (no)
HK (1) HK1052711A1 (no)
NO (1) NO331741B1 (no)
NZ (1) NZ521735A (no)
PT (1) PT1272507E (no)
WO (1) WO2001077145A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001250683B2 (en) * 2000-04-12 2006-06-29 Ge Healthcare As Peptide-based compounds
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
CA2452923C (en) * 2001-07-10 2012-02-07 Amersham Health As Peptide-based compounds for targeting integrin receptors
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
EP1493747B1 (en) * 2002-04-11 2012-12-19 Daiichi Sankyo Company, Limited Process for producing modified peptide
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
DE602005017475D1 (de) 2004-03-04 2009-12-17 Ge Healthcare As Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie
CA2568601A1 (en) * 2004-06-16 2005-12-29 Ge Healthcare As Peptide-based compounds
PL1765863T3 (pl) 2004-06-16 2012-05-31 Ge Healthcare As Związki oparte na peptydach
AU2005265048B2 (en) * 2004-06-18 2011-06-16 Elamleh, David R. Intravascular imaging device and uses thereof
ES2358745T3 (es) * 2004-11-22 2011-05-13 Ge Healthcare As Agentes de contraste para señalar matriz extracelular.
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2007042504A2 (fr) 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
CN101528270A (zh) * 2006-08-28 2009-09-09 通用电气健康护理有限公司 基于68Ga标记的肽的放射性药物
EP2101826B1 (en) * 2006-12-11 2010-06-23 GE Healthcare AS Radiolabelled peptide based compounds and uses thereof
US20090004119A1 (en) * 2007-06-27 2009-01-01 Ge Healthcare As Polymers
DE102007036570A1 (de) 2007-08-03 2009-02-19 Siemens Ag Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
WO2017069627A1 (en) * 2015-10-23 2017-04-27 Universiteit Twente Integrin binding peptides and uses thereof
EP3668532A4 (en) * 2017-08-19 2021-09-01 Ohio State Innovation Foundation INNOVATIVE PEPTIDE BASED CANCER IMAGING AGENTS
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
EP3970801A4 (en) * 2019-05-14 2022-11-02 Ichimaru Pharcos Co., Ltd. RAS INHIBITOR PEPTIDE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
EP0299795B1 (en) 1987-07-16 1992-03-18 Nycomed As Aminopolycarboxylic acids and derivatives thereof
US5753627A (en) * 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
IE901736L (en) 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
UA43823C2 (uk) 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
WO1997006791A1 (en) 1995-08-14 1997-02-27 The Scripps Research Institute METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
EP0987275B1 (en) 1995-09-11 2008-01-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo
CA2242647A1 (en) 1996-01-10 1997-07-17 Amersham Health As Contrast media
EP0907382A1 (de) 1996-02-09 1999-04-14 Steinel GmbH &amp; Co. KG Vorrichtung zum verdunsten eines flüssigen wirkstoffes
AU4412297A (en) 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
HUP0002070A2 (hu) 1997-05-28 2000-10-28 Genvec, Inc. Alternatív módon célba juttatott adenovírus
GB9711115D0 (en) 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
WO1999039734A1 (en) 1998-02-06 1999-08-12 The Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
AU2001250683B2 (en) * 2000-04-12 2006-06-29 Ge Healthcare As Peptide-based compounds
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser

Also Published As

Publication number Publication date
DE60111733D1 (de) 2005-08-04
HK1052711A1 (zh) 2003-09-26
KR20020087973A (ko) 2002-11-23
WO2001077145A3 (en) 2002-05-10
CN1230441C (zh) 2005-12-07
DK1272507T3 (da) 2005-10-03
ATE298763T1 (de) 2005-07-15
KR100879702B1 (ko) 2009-01-21
CA2405469A1 (en) 2001-10-18
US7351790B2 (en) 2008-04-01
CA2405469C (en) 2012-03-20
KR100866666B1 (ko) 2008-11-04
AU2001250683B2 (en) 2006-06-29
JP5043271B2 (ja) 2012-10-10
US20030204049A1 (en) 2003-10-30
US8404802B2 (en) 2013-03-26
CN1436195A (zh) 2003-08-13
NZ521735A (en) 2004-12-24
EP1272507B1 (en) 2005-06-29
DE60111733T2 (de) 2006-05-18
ES2244607T3 (es) 2005-12-16
PT1272507E (pt) 2005-11-30
EP1272507A2 (en) 2003-01-08
AU5068301A (en) 2001-10-23
WO2001077145A2 (en) 2001-10-18
NO331741B1 (no) 2012-03-19
US20080187493A1 (en) 2008-08-07
KR20080036662A (ko) 2008-04-28
JP2003531835A (ja) 2003-10-28

Similar Documents

Publication Publication Date Title
NO20024932D0 (no) Kontrastmiddel
MXPA04000173A (es) Compuestos basados en peptidos.
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NO20071880L (no) Diagnostic Compounds
NO20040402L (no) Peptidbaserte multimere malrettede kontrastmidler
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
MA28843B1 (fr) Therapie d&#39;association utilisant des proteines de fusion de trasferrine comprenant glp-1
ATE442379T1 (de) Bildgebende agentien auf basis bizyklischer peptide
DE50209802D1 (de) Naht-set für medizinische zwecke
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
SE9901077D0 (sv) Novel use
WO2008026040A3 (en) 68ga-labeled peptide-based radiopharmaceuticals
BRPI0608287A2 (pt) agente endoparasiticida
ATE352567T1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
NO20065806L (no) Peptid-baserte forbindelser
SE0301650D0 (sv) Novel compounds
FR2894113B1 (fr) Instrument d&#39;enveloppage de la main sous la forme d&#39;un gant.
ITMI20030550A1 (it) Macchina ad architettura modulare per l&#39;esecuzione di analisi mediche.
BR0316369B1 (pt) vestimenta para proteção parcial do corpo contra agentes biológicos.
SE0500291L (sv) New composition and the use thereof
IT251622Y1 (it) Sandalo pinnato ad uso degli assistenti bagnanti.
ITRC20050014A1 (it) &#34;CARDIOPASTA - La pasta che fa bene al cuore&#34;.
ITTV20030144A1 (it) Erogatore per doccia particolarmente ad uso ritemprante o terapeutico.
IT1317345B1 (it) Procedimento perfezionato per la realizzazione di tessuti non-tessutiagugliati.
HN1999000192A (es) Antagonistas de 54t1 para terapia antidepresiva

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees